Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 4,500 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $48.90, for a total value of $220,050.00. Following the transaction, the insider directly owned 1,078 shares of the company’s stock, valued at $52,714.20. The trade was a 80.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Siegal also recently made the following trade(s):

• On Friday, June 26th, Jonathan Siegal sold 2,732 shares of Vericel stock. The stock was sold at an average price of $44.90, for a total value of $122,666.80.

Vericel Stock Performance

VCEL opened at $45.96 on Friday. The stock has a market capitalization of $2.35 billion, a PE ratio of 97.79 and a beta of 1.07. The stock’s 50 day moving average price is $41.95 and its 200-day moving average price is $37.39. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $49.32.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $77.46 million during the quarter, compared to analyst estimates of $72.70 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%.The firm’s revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) earnings per share. Research analysts forecast that Vericel Corporation will post 0.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on VCEL shares. Weiss Ratings upgraded shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Vericel in a research report on Tuesday. TD Cowen upped their target price on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday. Finally, Canaccord Genuity Group set a $60.00 target price on Vericel in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $58.40.

Key Headlines Impacting Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported second-quarter revenue of $77.5 million, up 22% year over year and above the $72.7 million consensus estimate. Earnings were $0.04 per share, beating expectations for a $0.04 loss, while net income reached $2.2 million and free cash flow was $14.3 million. Vericel Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $330 million-$340 million, a range that brackets or modestly exceeds the $331.9 million analyst consensus. MACI revenue growth of 23% was a key contributor to the quarterly performance. Vericel Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The board authorized a $200 million share-repurchase program, which could support earnings per share and signal confidence in Vericel’s cash-generation outlook. Share Repurchase Program Announcement
• Positive Sentiment: Truist reaffirmed its Buy rating and increased its price target to $58 from $54. HC Wainwright also reaffirmed a Buy rating, reinforcing the favorable analyst view. Truist Financial Analyst Rating HC Wainwright Analyst Rating
• Neutral Sentiment: The earnings-call transcript and presentation provide additional operating details but do not indicate a separate material catalyst beyond the reported results and guidance. Q2 2026 Earnings Presentation
• Neutral Sentiment: Analyst sentiment is not unanimous, and Vericel trades at a high earnings multiple, leaving the shares sensitive to any slowdown in growth or weaker-than-expected future results. Conflicting Analyst Sentiment

Institutional Trading of Vericel

A number of hedge funds have recently modified their holdings of VCEL. Handelsbanken Fonder AB increased its stake in shares of Vericel by 2.2% in the 2nd quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock worth $1,027,000 after acquiring an additional 500 shares in the last quarter. GAMMA Investing LLC lifted its position in Vericel by 17.7% during the 2nd quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 283 shares during the period. Versant Capital Management Inc boosted its stake in Vericel by 651.3% during the second quarter. Versant Capital Management Inc now owns 2,667 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 2,312 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Vericel by 18.4% during the first quarter. Glenmede Trust Co. NA now owns 15,097 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 2,348 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Vericel by 19.7% in the first quarter. Bank of America Corp DE now owns 1,098,771 shares of the biotechnology company’s stock worth $35,347,000 after purchasing an additional 180,761 shares during the period.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.